title: Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer.
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
authors.forename: Andreas
authors.initials: A
authors.lastname: Synetos
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tousoulis
authors.forename: Eleftherios
authors.initials: E
authors.lastname: Tsiamis
authors.forename: Archontoula
authors.initials: A
authors.lastname: Michelongona
authors.forename: Flora
authors.initials: F
authors.lastname: Zagouri
authors.forename: Aristotle
authors.initials: A
authors.lastname: Bamias
authors.forename: Meletios Athanasios
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Stella
authors.initials: S
authors.lastname: Kyvelou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kapelakis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Toutouzas
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D009362:Neoplasm Metastasis; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab